Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 11/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.45 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4827090 | 0.85 | ALDH1A1 (0.51) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL17063326 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL17063344 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL19461283 | 0.78 | GRIN2B (0.47) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL17063250 | 0.77 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL29671511 | 0.77 | SMN1; SMN2 (0.65) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL28690825 | 0.76 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL19461116 | 0.75 | GRIN2B (0.46) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL15140566 | 0.73 | SMN1; SMN2 (0.72) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL458805 | 0.73 | SMN1; SMN2 (0.72) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419986-B2 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| US-7335666-B2 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2008-02-26 | — | — | US | disclosed |
| CN-100352820-C | Antidepressant azacyclomethyl derivatives of heterocycle-fused benzodioxans | WYETH CORP (US) | 2007-12-05 | — | — | CN | disclosed |
| US-20070004702-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
| US-20060293301-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2006-12-28 | — | — | US | disclosed |
| US-7135479-B2 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH (US) | 2006-11-14 | — | — | US | disclosed |
| CN-1701076-A | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH CORP (US) | 2005-11-23 | — | — | CN | disclosed |
| EP-1537119-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | Wyeth (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040132714-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH | 2004-07-08 | — | — | US | disclosed |
| WO-2004024730-A1 | ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXANS | WYETH (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293301-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | CRH, HTR5A, DBH | SMN1; SMN2 2518/4885NPC1 2592/4885RAB9A 1342/4885 |
| US-20070004702-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | CRH, CYP19A1, HTR5A | SMN1; SMN2 2730/4885NPC1 2711/4885RAB9A 1121/4885 |
| US-20040132714-A1 | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | CYP19A1, CRH, CYP17A1 | SMN1; SMN2 2658/4885NPC1 2325/4885RAB9A 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.